following an abbreviated submission:
risankizumab (Skyrizi ®) is accepted for use within NHSScotland.
Indication under review: for the treatment of patients 16 years and older with moderately to severely active Crohn's disease who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy, or if such therapies are not advisable.
Risankizumab offers an additional treatment choice in the therapeutic class of interleukin inhibitor in this setting.
This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower.
Download detailed advice742KB (PDF)
Medicine details
- Medicine name:
- risankizumab (Skyrizi)
- SMC ID:
- SMC2534
- Indication:
For treatment of people 16 years and older with moderately to severely active CD who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy, or if such therapies are not advisable
- Pharmaceutical company
- AbbVie Ltd
- BNF chapter
- Gastro-intestinal system
- Submission type
- Abbreviated
- Status
- Accepted
- Date advice published
- 13 November 2023